SCHEMBL4188701

SCHEMBL4188701

COc1ccc(S)c(C(C)=O)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.59
HPGD P15428 3/20 0.59
CYP3A4 P08684 1/20 0.59
MAPK1 P28482 1/20 0.59
MAPT P10636 3/20 0.48
KMT2A Q03164 3/20 0.48
KDM4E B2RXH2 3/20 0.47
GAA P10253 1/20 0.47
MAOB P27338 1/20 0.47
HTT P42858 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
RAB9A P51151 2/20 0.47
NPC1 O15118 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.46
CYP1A2 P05177 2/20 0.45
CYP2C19 P33261 2/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
AKR1C3 P42330 3/20 0.44
AKR1C2 P52895 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3175661 0.85 SMN1; SMN2 (0.59) ALDH1A1HPGDMAPTKMT2AKDM4E
SCHEMBL14996626 0.83 KDM4E (0.50) ALDH1A1HPGDCYP3A4MAPK1MAPT
SCHEMBL9214526 0.83 KDM4E (0.60) ALDH1A1HPGDCYP3A4MAPK1MAPT
SCHEMBL13094612 0.82 ALDH1A1 (0.71) ALDH1A1HPGDCYP3A4MAPK1MAPT
SCHEMBL18661182 0.80 MTNR1A (0.55) ALDH1A1HPGDMAPTKMT2AKDM4E
SCHEMBL22242900 0.80 MAPT (0.44) ALDH1A1HPGDCYP3A4MAPK1MAPT
SCHEMBL1986986 0.78 ALDH1A1 (0.61) ALDH1A1HPGDCYP3A4MAPK1MAPT
SCHEMBL29581343 0.78 MAPT (0.68) ALDH1A1HPGDCYP3A4MAPK1MAPT
SCHEMBL885028 0.78 MAPT (0.68) ALDH1A1HPGDCYP3A4MAPK1MAPT
SCHEMBL29445806 0.78 ALDH1A1 (0.72) ALDH1A1HPGDCYP3A4MAPK1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7576122-B2 Ophthalmic compositions for treating ocular hypertension MERCK & CO. INC. (US) 2009-08-18 US disclosed
EP-1664011-A4 OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION MERCK & CO INC (US) 2009-02-25 EP disclosed
US-20080287489-A1 Ophthalmic compositions for treating ocular hypertension MERCK SHARP & DOHME CORP. 2008-11-20 US disclosed
US-20060276504-A1 Ophthalmic compositions for treating ocular hypertension MERCK SHARP & DOHME CORP. 2006-12-07 US disclosed
EP-1664011-A2 OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION Merck & Co., Inc. (US) 2006-06-07 EP disclosed
WO-2005020917-A2 OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION MERCK & CO., INC. (US) 2005-03-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276504-A1 Ophthalmic compositions for treating ocular hypertension KCNH2, KCNJ11, KCNN1 ALDH1A1 938/4885HPGD 252/4885CYP3A4 3953/4885
US-20080287489-A1 Ophthalmic compositions for treating ocular hypertension KCNH2, KCNH3, KCNJ11 ALDH1A1 899/4885HPGD 282/4885CYP3A4 3932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.